lamotrigine
lamotrigine is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: lamotrigine; Generic name: LAMOTRIGINE; Drug class: Anti-epileptic Agent [EPC].
| Brand name | lamotrigine |
|---|---|
| Generic name | LAMOTRIGINE |
| Drug class | Anti-epileptic Agent [EPC] |
| Manufacturer | Alembic Pharmaceuticals Inc. |
| Used for | 1 INDICATIONS AND USAGE Lamotrigine is indicated for: Epilepsy - adjunctive therapy in patients aged 2 years and older: · partial-onset seizures. · primary generalized tonic-clonic (PGTC) seizures. · generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy - monotherapy in patients aged 16 years and older : Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder : Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therap |
| Dosage | 2 DOSAGE AND ADMINISTRATION · Dosing is based on concomitant medications, indication, and patient age. ( 2.1 , 2.2 , 2.3 , 2.4 ) · To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations should not be exceeded. ( 2.1 ) · Do not restart lamotrigine in patients who discontinued due to rash unless the potential benefits clearly outweigh the risks. ( 2.1 , 5.1 ) · Adjustments to maintenance doses will be necessary in most patients starting or stopping estroge |
| Warnings | WARNING: SERIOUS SKIN RASHES Lamotrigine can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.3% to 0.8% in pediatric patients (aged 2 to 17 years) and 0.08% to 0.3% in adults receiving lamotrigine. One rash-related death was reported in a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking lamotrigine as adjunctive therap |
| Active ingredient(s) | LAMOTRIGINE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05cba628-b12c-44d8-89a8-3522fe417cc1 |